Literature DB >> 3780367

Placental transfer of omeprazole in maternal and fetal sheep.

M S Ching, D J Morgan, G W Mihaly, K J Hardy, R A Smallwood.   

Abstract

The placental transfer of omeprazole was studied over a 4-fold dose range in 7 nonanesthetized near-term pregnant sheep. There was a 5 to 1 maternal to fetal transplacental gradient of steady-state total omeprazole concentrations after both low dose (maternal plasma 556 +/- 361 ng/ml, fetal plasma 101 +/- 57 ng/ml) and high dose (maternal plasma 2,660 +/- 1,130 ng/ml, fetal plasma 563 +/- 182 ng/ml). Although this was in part due to differences in plasma protein binding between mother (unbound fraction 6.6 +/- 5.5%) and fetus (unbound fraction 11.9 +/- 2.4%), a 2 to 1 maternal to fetal gradient of steady-state unbound omeprazole concentration was still present (144 +/- 73 ng/ml vs. 64 +/- 32 ng/ml). Fetal omeprazole total plasma concentrations correlated strongly with maternal total drug concentrations (r = 0.84, p less than 0.025) and with the inverse of maternal omeprazole total systemic clearance (r = 0.77, p less than 0.05), indicating that maternal drug disposition was a major determinant of fetal omeprazole plasma concentrations. Urinary clearance of omeprazole was low in both mother (0.137 +/- 0.046 ml/min) and fetus (0.067 +/- 0.039 ml/min). This study demonstrates that the fetus is exposed to about one half of the unbound omeprazole concentration in maternal plasma and suggests that the extent of fetal exposure is largely dictated by maternal drug distribution and elimination characteristics.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3780367     DOI: 10.1159/000457111

Source DB:  PubMed          Journal:  Dev Pharmacol Ther        ISSN: 0379-8305


  5 in total

Review 1.  Clinical pharmacokinetics of drugs used in the treatment of gastrointestinal diseases (Part II).

Authors:  K Lauritsen; L S Laursen; J Rask-Madsen
Journal:  Clin Pharmacokinet       Date:  1990-08       Impact factor: 6.447

2.  The safety of fetal exposure to proton-pump inhibitors during pregnancy.

Authors:  I Matok; A Levy; A Wiznitzer; E Uziel; G Koren; R Gorodischer
Journal:  Dig Dis Sci       Date:  2011-10-30       Impact factor: 3.199

Review 3.  Safety of potent gastric acid inhibition.

Authors:  Carlos Martín de Argila
Journal:  Drugs       Date:  2005       Impact factor: 9.546

Review 4.  Omeprazole. An updated review of its pharmacology and therapeutic use in acid-related disorders.

Authors:  D McTavish; M M Buckley; R C Heel
Journal:  Drugs       Date:  1991-07       Impact factor: 9.546

5.  Use of proton pump inhibitors during pregnancy and rates of major malformations: a meta-analysis.

Authors:  Shekoufeh Nikfar; Mohammad Abdollahi; Myla E Moretti; Laura A Magee; Gideon Koren
Journal:  Dig Dis Sci       Date:  2002-07       Impact factor: 3.199

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.